Ken Wang

Integrating population heterogeneity in drug research and early development: a proactive strategy.

Population heterogeneity in disease biology, drug exposure and treatment response is often addressed only after development has progressed, limiting generalizability and increasing late-stage risk. We propose an anticipate-verify-influence framework to integrate clinically relevant variability from research through dev...